ERBB2 and neoplasm: Thirdly, the addition of the HER2 antagonist trastuzumab to FET treatment resulted in a significant increase in tumour cell death that correlated with HER2 status, and HER2-enriched molecular subtypes also underwent significantly higher cell death responses compared to both TNBC and luminal A subgroups.